Statute Details
- Title: Medicines (Veterinary Medicinal Products) (Import and Product Licences) Regulations
- Act Code: MA1975-RG1
- Legislation Type: Subsidiary legislation (sl)
- Authorising Act: Medicines Act (Chapter 176, Section 74)
- Commencement: Not stated in the extract provided (document shows historical commencement references)
- Current Version Status: Current version as at 27 Mar 2026 (per document header)
- Key Provisions (Extract): Regulations 3–14 (including validity periods, application requirements, change notifications, safety/efficacy information, records, substandard products, fees, and penalties)
- Core Regulatory Themes: Licensing of veterinary medicinal products and imports; ongoing data/safety reporting; recordkeeping; controls for substandard products; administrative fees and criminal penalties
What Is This Legislation About?
The Medicines (Veterinary Medicinal Products) (Import and Product Licences) Regulations (“the Regulations”) create a licensing framework for veterinary medicinal products in Singapore, focusing on two practical areas: (1) licensing of the product itself (product licences and provisional product licences), and (2) licensing of the importation of veterinary medicinal products (import licences). In plain terms, the Regulations ensure that veterinary medicines brought into Singapore and sold or supplied there are subject to prior approval and ongoing regulatory oversight.
The Regulations are designed to protect animal health, and also to address risks to humans and the wider environment. They require applicants to submit scientific and safety-related information, including chemical/pharmaceutical studies, animal testing, and assessments of hazards to man, livestock and wildlife. After a licence is granted, the holder must continue to engage with the regulator—for example, by notifying changes to product particulars, reporting adverse effects, and informing the licensing authority if new information undermines the safety, quality, or efficacy data relied upon for approval.
For importers, the Regulations impose recordkeeping obligations and provide the licensing authority with powers to direct withholding from sale/supply/exportation where a product is suspected or found to be substandard. The Regulations also set out fees and create a criminal penalty regime for non-compliance with specified duties and directions.
What Are the Key Provisions?
1. Validity periods for product and provisional product licences (Regulation 3)
A product licence (other than a provisional product licence) is granted for a period of 5 years, or a shorter period as the licensing authority may determine. A provisional product licence is granted for 2 years, or a shorter period as determined by the licensing authority. This distinction is important for practitioners advising on regulatory strategy: a provisional licence may be used where the regulator permits a shorter-term approval pathway, but the holder must plan for renewal or transition to a full product licence within the relevant timeframe.
2. Import licences are consignment-specific and time-limited (Regulation 4)
Every import licence is valid only for one consignment of veterinary medicinal products for which the application was made. The licence is in force for one month from the date of issue. This means importers cannot rely on a licence as a general authorisation for multiple shipments; each consignment requires its own licensing process. Practically, counsel should ensure supply chain planning aligns with the one-month validity window and that applications are made with sufficient lead time.
3. Application requirements for product licences and provisional product licences (Regulations 5 and 6)
Applications must be made to the licensing authority in the required form and manner, accompanied by the information, documents, samples and other material the authority may require (Regulation 5(1)). A crucial procedural requirement is that there must be a separate application for each veterinary medicinal product (Regulation 5(2)). However, Regulation 5(3) allows a single application to cover 2 or more veterinary medicinal products where they share the same pharmaceutical form and consist of either (a) a single active constituent in different strengths, or (b) a mixture of active constituents of different strengths but in the same proportion. This “grouping” provision can reduce administrative burden where products are essentially strength variants or proportionally equivalent formulations.
Regulation 6 specifies the types of particulars that must be submitted, including: (a) chemical, pharmaceutical, experimental and biological studies; (b) animal tests and studies; (c) possible hazards to man, livestock and wildlife; and (d) precautions or contra-indications. For lawyers, this is a substantive evidentiary framework: it signals that licensing is grounded in scientific dossiers and risk assessment, and it supports arguments about what information must be available to justify approval and what gaps may trigger refusal or conditions.
4. Ongoing duties: changes, new information, adverse effects, and withdrawal decisions (Regulations 7–10)
Once licensed, the holder must act promptly. Regulation 7 requires the holder to forthwith inform the licensing authority of any material change made or proposed in the particulars contained in the application. The regulation enumerates the relevant areas: specifications of the product; specifications of constituents; composition; and methods/procedures ensuring compliance with specifications. The word “material” is not defined in the extract, but the listed categories indicate that changes affecting identity, composition, quality control, or compliance methods are likely to be treated as material. Practitioners should therefore advise clients to implement change-control processes and to assess whether changes require regulatory notification before implementation.
Regulation 8 imposes a duty to notify the licensing authority of any information received that casts doubt on the continued validity of data submitted for assessing safety, quality or efficacy. This is a continuing validity concept: even after approval, new evidence can undermine the basis of approval, and the holder must disclose it.
Regulation 9 requires reporting of adverse effects on human beings or animals (or both) associated with the use of the veterinary medicinal product or its constituents. The licensing authority may require copies of reports. Regulation 10 requires the holder to notify the authority forthwith of any decision to withdraw from sale, supply or exportation, and to state the reason. Together, these provisions create a lifecycle approach: safety surveillance and market withdrawal transparency are part of the licence conditions.
5. Records and inspection rights for importers (Regulation 11)
An importer must keep readily available for inspection by the licensing authority records of imports and distribution of veterinary medicinal products. When directed, the importer must submit such records. Records must not be destroyed for 5 years from the date of importation, and must be kept in a way that facilitates withholding from sale/supply/exportation of any veterinary medicinal products. This is a key compliance obligation for regulated businesses: it supports traceability and rapid regulatory action in recalls or quality investigations.
6. Controls for suspected or confirmed substandard products (Regulation 12)
Where a veterinary medicinal product is suspected or found not to conform as regards strength, quality or purity with the product specification or with the Medicines Act or regulations, the licensing authority may direct the importer or any person in possession of the product to withhold it from sale, supply or exportation for a specified period. This provision is significant because it provides an enforcement lever that does not necessarily require a final determination before action—“suspected” products can be subject to withholding directions. Lawyers advising importers should treat this as a high-risk area requiring immediate operational response and documentation.
7. Fees (Regulation 13)
The Regulations set fixed fees: $3 per consignment for an import licence; $50 per product for a product licence; and $25 per product for a provisional product licence. While the amounts are modest, the per-consignment and per-product structure affects budgeting and compliance planning, especially for businesses importing multiple consignments or holding multiple product licences.
8. Penalty for non-compliance (Regulation 14)
Any person who contravenes or fails to comply with Regulations 7, 8, 9, 10 or 11, or fails to comply with a direction under Regulation 12, commits an offence. On conviction, the person is liable to a fine not exceeding $2,000. Although the maximum fine in the extract may appear limited, the offence provisions are legally consequential: they create criminal exposure for compliance failures and for non-response to withholding directions. For practitioners, this underscores the need for robust compliance systems, timely reporting (“forthwith”), and documented decision-making.
How Is This Legislation Structured?
The Regulations are structured as a sequence of operational rules, moving from licensing validity and application mechanics to post-licensing duties and enforcement. The numbering in the extract indicates the following flow:
Regulation 1 sets the citation. Regulation 2 provides a definition of “importer”. Regulations 3 and 4 address validity periods for product licences and import licences. Regulations 5 and 6 govern applications and required particulars. Regulations 7–10 impose ongoing notification duties relating to changes, new information, adverse effects, and withdrawal decisions. Regulation 11 sets recordkeeping and inspection requirements for importers. Regulation 12 provides the licensing authority’s power to direct withholding of substandard (or suspected substandard) products. Regulation 13 sets fees, and Regulation 14 provides the penalty for specified contraventions and failures to comply with directions.
Who Does This Legislation Apply To?
The Regulations apply to persons involved in the importation and licensing of veterinary medicinal products in Singapore. In particular, they regulate: (a) product licence holders and provisional product licence holders (through ongoing duties to notify changes, adverse effects, and withdrawal decisions); and (b) importers (through consignment-based import licensing, recordkeeping, and compliance with withholding directions).
While the extract defines “importer” as an importer of veterinary medicinal products, Regulation 12 extends the withholding power not only to importers but also to any person in possession of the product. Therefore, the practical scope includes distributors, warehouse operators, and other intermediaries who may hold stock pending regulatory action.
Why Is This Legislation Important?
This regulatory instrument is important because it operationalises the Medicines Act’s licensing objectives for veterinary medicinal products. It provides a structured pathway for approval (product/provisional product licences), ensures that importation is controlled at the consignment level, and requires continuous engagement with the regulator after approval. For practitioners, the Regulations are not merely administrative: they embed substantive scientific and risk-assessment expectations through the required particulars (Regulation 6) and through the continuing validity and adverse effects reporting duties (Regulations 8 and 9).
From an enforcement perspective, the Regulations also create practical compliance obligations that can be audited or inspected. Recordkeeping for five years (Regulation 11) supports traceability and enables rapid regulatory action. The authority’s ability to direct withholding for suspected substandard products (Regulation 12) means that compliance teams must be prepared for urgent operational measures, including quarantine of stock, communication with supply chain partners, and documentation of product status and batch traceability.
Finally, the penalty provision (Regulation 14) gives the Regulations teeth. Although the maximum fine is capped in the extract, the existence of criminal liability for failures to notify or to comply with directions should be treated seriously in corporate compliance programmes. Lawyers advising regulated entities should therefore focus on governance: change-control procedures, adverse event reporting workflows, regulatory correspondence protocols, and record retention policies aligned with the five-year requirement.
Related Legislation
- Medicines Act (Chapter 176) (authorising provision: Section 74)
Source Documents
This article provides an overview of the Medicines (Veterinary Medicinal Products) (Import and Product Licences) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.